This from Pharmalot reporting on analysts assessments of which drug makers in Japan would have greatest revenues at risk if there is long-lasting disruption due to the earthquake and the tsunami and new nuclear power plant incidents in its aftermath.
Analysts calculated the percentage of a Big Pharma firm's total revenue that was centered in Japan. Percentages of total revenue and total amount are listed below:
- Novartis - 10.9% and $3.3 billion
- Merck - 8.2% and $3.8 billion
- AstraZeneca 7.9% and $2.6 billion
- Bristol-Myers Squibb 3% and $585 million
Almost all of these companies have their manufacturing facilties more than 200 mles from the hardest hit areas by the earthquake (Sendai). The also have business continuity plans in place to ensure at least a few months supply.